For China and China HK media use only

BEIJING, China – July 13, 2021 – Brii Biosciences Limited (“Brii Biosciences” or the “Company”, stock code: 2137.HK), a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases and other illnesses which have significant public health burdens, was officially listed on the Main Board of the Stock Exchange of Hong Kong Limited (“SEHK”) today.

Brii Biosciences issued 111,580,000 shares globally at a final offer price of HK$22.25 per share, raising approximately HK$2.482 billion gross proceeds (assuming the over-allotment option in respect of 16,737,000 shares is not exercised).

Brii Biosciences is a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden. With a business model combining internal discovery and in-licensing, Brii Biosciences has built a pipeline of more than ten innovative product candidates that focus on infectious diseases and central nervous system (CNS) diseases and range from preclinical and clinical stage programs. Currently the Company is developing therapies against significant infectious diseases such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections and SARs-CoV-2 infection (COVID-19), as well as innovative therapies to address CNS disorders, such as postpartum depression (PPD) and major depressive disorder (MDD).

Zhi Hong, Ph.D., CEO of Brii Biosciences, said: “Listing on the Hong Kong Stock Exchange marks an important milestone for our company. Brii Biosciences enjoys unique strengths in the R&D of novel drugs. By leveraging our remarkable senior management as well as our experience of conducting multi-regional clinical trials, we will continue to expand our pipeline through our in-house R&D efforts, and in-licenses or collaborations on appropriate drug candidates, as we aim to tackle public health challenges with our innovation and insight to benefit more patients.”

****************************************

About Brii Biosciences
Brii Biosciences Limited (“Brii Biosciences” or the “Company”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.